SCHEMBL6683273

SCHEMBL6683273

O=C(NCc1ccc(F)cc1)c1ccc2c(c1)C(=O)C(Cc1ccc(F)c(F)c1)C(=O)N2

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.49
CNR1 P21554 1/20 0.47
LMNA P02545 6/20 0.46
TP53 P04637 3/20 0.46
RXFP1 Q9HBX9 2/20 0.44
THRB P10828 1/20 0.44
ROCK2 O75116 1/20 0.42
ROCK1 Q13464 1/20 0.42
HTR7 P34969 1/20 0.42
HDAC2 Q92769 1/20 0.41
HDAC8 Q9BY41 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41
DRD2 P14416 1/20 0.40
BRD4 O60885 1/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
POLB P06746 2/20 0.40
GRK5 P34947 1/20 0.40
MAPK1 P28482 1/20 0.40
ALDH1A1 P00352 1/20 0.39
GAA P10253 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6680500 0.92 MAPT (0.47) MAPTCNR1LMNATP53RXFP1
SCHEMBL6684875 0.92 MAPT (0.49) MAPTCNR1LMNATP53RXFP1
SCHEMBL6684559 0.90 MAPT (0.53) MAPTCNR1LMNATP53RXFP1
SCHEMBL6683152 0.90 MAPT (0.53) MAPTLMNAROCK2ROCK1DRD2
SCHEMBL6681366 0.89 MAPT (0.56) MAPTCNR1LMNATP53RXFP1
SCHEMBL6679778 0.89 MAPT (0.47) MAPTCNR1LMNATP53RXFP1
SCHEMBL6678534 0.89 MAPT (0.48) MAPTCNR1LMNATP53RXFP1
SCHEMBL6681850 0.83 HDAC2 (0.42) HDAC2HDAC8HDAC6L3MBTL1POLB
SCHEMBL6680173 0.82 ALDH1A1 (0.53) MAPTLMNATP53RXFP1THRB
SCHEMBL6682598 0.82 MAPT (0.51) MAPTLMNATP53ROCK2ROCK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040043985-A1 6,6-Fused heteroaryl derivatives as matrix metalloproteinase inhibitors HICKS JAMES LESTER (US) 2004-03-04 US disclosed
WO-2004014388-A1 6,6-FUSED HETEROARYL DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2004-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040043985-A1 6,6-Fused heteroaryl derivatives as matrix metalloproteinase inhibitors MMP13, MMP26, MMP9 MAPT 2365/4885CNR1 3350/4885LMNA 2566/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.